Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Milk membrane may tame metabolic syndrome inflammation

NCT ID NCT03860584

Disease control Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a natural part of milk fat called milk fat globule membrane (MFGM) can lower harmful gut bacteria products in the blood and improve health markers in adults with metabolic syndrome. Thirty people with metabolic syndrome followed a controlled diet with either MFGM-enriched milk or a placebo milk for two weeks each. Researchers measured blood toxins, blood sugar, cholesterol, and gut health to see if MFGM could reduce inflammation and improve metabolic control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jul 2019

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Serum Glucose 100-126 mg/dl * Waist C \>89/102 cm; F/M * Serum HDL-C: \<50/40 mg/dl; F/M * Serum triglyceride: \>150 mg/dl * Blood Pressure \>130/85 mmHg Exclusion Criteria: * Unstable body mass (±2 kg over prior 3-mo) * Vegetarian * Food allergies or lactose intolerance * User of dietary supplements or probiotics (within past 1-mo) * Pregnancy, lactation, changes in birth control (within 6-mo) * Any gastrointestinal disorders * Chronic diarrhea * Smoker * Excess alcohol (\>2 drinks/d) * Excess aerobic exercise (\>5 h/wk) * Recent antibiotic or anti-inflammatory agent use * Blood Pressure \>140/90 mmHg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic endotoxemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Inflammation metabolic syndrome X Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic endotoxemia Metabolic syndrome

Contacts and locations

Locations

  • The Ohio State University

    Columbus, Ohio, 43201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.